Liposomes modified by carbohydrate ligands can target B cells for the treatment of B-cell lymphomas

References

• Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology2007, 233–242 (2007).
   Google Scholar
• Ratanatharathorn V, Pavletic S, Uberti JP. Clinical applications of rituximab in allogeneic stem cell transplantation: anti-tumor and immunomodulatory effects. Cancer Treat. Rev.35(8), 653–661 (2009).
   PubMedGoogle Scholar
• Cartron G, Dacheux L, Salles G et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgRIIIa gene. Blood99(3), 754–758 (2002).
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol.21(21), 3940–3947 (2003).
   PubMed Web of Science ®Google Scholar
• Ghielmini M, Rufibach K, Salles G et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann. Oncol., 16(10), 1675–1682 (2005).
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene22(47), 7359–7368 (2003).
   PubMed Web of Science ®Google Scholar
• Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of Bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin. Cancer Res.7(3), 709–723 (2001).
   PubMed Web of Science ®Google Scholar
• Selenko N, Maidic O, Draxier S et al. CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia15(10), 1619–1626 (2001).
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol.16(8), 2825–2833 (1998).
   PubMed Web of Science ®Google Scholar
• Davis TA, Grillo-Lopez AJ, White CA et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol.18(17), 3135–3143 (2000).
   PubMed Web of Science ®Google Scholar
• Weiner GJ, Bowles JA, Link BK, Campbell MA, Wooldridge JE, Breitmeyer JB. An anti-CD20 monoclonal antibody (mAb) with enhanced affinity for CD16 activates NK cells at a lower concentrations and more effectively than rituximab. Blood106, 108(8), 2648–2654 (2005).
   Google Scholar
• Mossner E, Brunker P, Moser S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood115(22), 4393–4402 (2010).
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Margulies I, Stetler-Stevenson M, Wang QC, FitzGerald DJ, Pastan I. Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin. Cancer Res.6(4), 1476–1487 (2000).
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, Bergeron K et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med.345(4), 241–247 (2001).
   PubMed Web of Science ®Google Scholar
• DiJoseph JF, Dougher MM, Kalyandrug LB et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin’s B-cell lymphoma. Clin. Cancer Res.12(1), 242–249 (2006).
   PubMed Web of Science ®Google Scholar
• Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia21(11), 2240–2245 (2007).
   PubMed Web of Science ®Google Scholar
• Du X, Beers R, Fitzgerald DJ, Pastan I. Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity. Cancer Res.68(15), 6300–6305 (2008).
   PubMed Web of Science ®Google Scholar
• Chen WC, Completo GC, Sigal DS, Crocker PR, Saven A, Paulson JC. In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood115(23), 4778–4786 (2010).
   PubMed Web of Science ®Google Scholar
• Castillo J, Winer E, Quesenberry P. Newer monoclonal antibodies for hematological malignancies. Exp. Hematol.36(7), 755–768 (2008).
   PubMed Web of Science ®Google Scholar
• Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin’s lymphoma. Annu. Rev. Med.59, 237–250 (2008).
   PubMed Web of Science ®Google Scholar
• Evans LS, Hancock BW. Non-Hodgkin lymphoma. Lancet362(9378), 139–146 (2003).
   PubMed Web of Science ®Google Scholar
• Haas KM, Sen S, Sanford IG, Miller AS, Poe JC, Tedder TF. CD22 ligand binding regulates normal and malignant B lymphocyte survival in vivo. J. Immunol.177(5), 3063–3073 (2006).
   PubMedGoogle Scholar
• Collins BE, Blixt O, Han S et al. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J. Immunol.177(5), 2994–3003 (2006).
   PubMed Web of Science ®Google Scholar
• Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. Eradication of minimal disease in severe combined immunodeficient mice with disseminated Daudi lymphoma using chemotherapy and an immunotoxin cocktail. Blood84(3), 702–707 (1994).
   PubMed Web of Science ®Google Scholar
• Newton DL, Hansen HJ, Mikulski SM, Goldenberg DM, Rybak SM. Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: potential for the treatment of non-Hodgkin lymphoma. Blood97(2), 528–535 (2001).
   PubMed Web of Science ®Google Scholar
• Cheng WW, Allen TM. Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma: a comparison of whole monoclonal antibody, Fab’ fragments and single chain Fv. J. Control. Release126(1), 50–58 (2008).
   PubMed Web of Science ®Google Scholar
• Zaccai NR, Maenaka K, Maenaka T et al. Structure-guided design of sialic acid-based Siglec inhibitors and crystallographic analysis in complex with sialoadhesin. Structure11(5), 557–567 (2003).
   PubMed Web of Science ®Google Scholar
• Blixt O, Han S, Liao L et al. Sialoside analogue arrays for rapid identification of high affinity siglec ligands. J. Am. Chem. Soc.130(21), 6680–6681 (2008).
   PubMed Web of Science ®Google Scholar
• Hartnell A, Steel J, Turley H, Jones M, Jackson DG, Crocker PR. Characterization of human sialoadhesin, a sialic acid binding receptor expressed by resident and inflammatory macrophage populations. Blood97(1), 288–296 (2001).
   PubMed Web of Science ®Google Scholar
• Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES. Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. Int. J. Cancer45(3), 481–485 (1990).
   PubMed Web of Science ®Google Scholar
• Eccles SA. Monoclonal antibodies targeting cancer: ‘magic bullets’ or just the trigger?. Breast Cancer Res.3(2), 86–90 (2001).
   PubMedGoogle Scholar
• Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov. Today9(15), 641–651 (2004).
   PubMed Web of Science ®Google Scholar
• Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer6(9), 714–727 (2006).
   PubMed Web of Science ®Google Scholar
• Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology233–242 (2007).
   PubMedGoogle Scholar
• Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov.4(2), 145–160 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor ME, Drickamer K. Paradigms for glycan-binding receptors in cell adhesion. Curr. Opin. Cell. Biol.19(5), 572–577 (2007).
   PubMed Web of Science ®Google Scholar
• Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell126(5), 855–867 (2006).
   PubMed Web of Science ®Google Scholar
• Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep.7(6), 599–604 (2006).
   PubMed Web of Science ®Google Scholar
• Brown JR, Crawford BE, Esko JD. Glycan antagonists and inhibitors: a fount for drug discovery. Crit. Rev. Biochem. Mol. Biol.42(6), 481–515 (2007).
   PubMed Web of Science ®Google Scholar
• Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat. Rev. Immunol.7(4), 255–266 (2007).
   PubMed Web of Science ®Google Scholar
• van Kooyk Y, Rabinovich GA. Protein–glycan interactions in the control of innate and adaptive immune responses. Nat. Immunol.9(6), 593–601 (2008).
   PubMed Web of Science ®Google Scholar
• Collins BE, Paulson JC. Cell surface biology mediated by low affinity multivalent protein–glycan interactions. Curr. Opin. Chem. Biol.8(6), 617–625 (2004).
   PubMed Web of Science ®Google Scholar
• Collins BE, Blixt O, DeSieno AR, Bovin N, Marth JD, Paulson JC. Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc. Natl Acad. Sci. USA101(16), 6104–6109 (2004).
   PubMedGoogle Scholar
• Lundquist JJ, Toone EJ. The cluster glycoside effect. Chem. Rev.102(2), 555–578 (2002).
   PubMed Web of Science ®Google Scholar
• Aviles A, Neri N, Castaneda C, Talavera A, Huerta-Guzman J, Gonzalez M. Pegylated liposomal doxorubicin in combination chemotherapy in the treatment of previously untreated aggressive diffuse large-B-cell lymphoma. Med. Oncol.19(1), 55–58 (2002).
   PubMed Web of Science ®Google Scholar
• Tsavaris N, Kosmas C, Vadiaka M et al. Pegylated liposomal doxorubicin in the CHOP regimen for older patients with aggressive (stages III/IV) non-Hodgkin’s lymphoma. Anti Cancer Res.22(3), 1845–1848 (2002).
   PubMed Web of Science ®Google Scholar
• Levine AM, Tulpule A, Espina B et al. Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin’s lymphoma: results of therapy and correlates of response. J. Clin. Oncol.22(13), 2662–2670 (2004).
   PubMed Web of Science ®Google Scholar
• Bruehl RE, Dasgupta F, Katsumoto TR et al. Polymerized liposome assemblies: bifunctional macromolecular selectin inhibitors mimicking physiological selectin ligands. Biochemistry40(20), 5964–5974 (2001).
   PubMedGoogle Scholar
• Ikehara Y, Niwa T, Biao L et al. A carbohydrate recognition-based drug delivery and controlled release system using intraperitoneal macrophages as a cellular vehicle. Cancer Res.66(17), 8740–8748 (2006).
   PubMed Web of Science ®Google Scholar
• Hashida N, Ohguro N, Yamazaki N et al. High-efficacy site-directed drug delivery system using sialyl-Lewis X conjugated liposome. Exp. Eye Res.86(1), 138–149 (2008).
   PubMed Web of Science ®Google Scholar
• Ikehara Y, Shiuchi N, Kabata-Ikehara S et al. Effective induction of anti-tumor immune responses with oligomannose-coated liposome targeting to intraperitoneal phagocytic cells. Cancer Lett.260(1–2), 137–145 (2008).
   PubMed Web of Science ®Google Scholar
• O’Reilly MK, Paulson JC. Siglecs as targets for therapy in immune-cell-mediated disease. Trends Pharmacol. Sci.30(5), 240–248 (2009).
   PubMed Web of Science ®Google Scholar
• Zhang H, Ma Y, Sun XL. Recent developments in carbohydrate-decorated targeted drug/gene delivery. Med. Res. Rev.30(2), 270–289 (2010).
   PubMed Web of Science ®Google Scholar